独家观察！企业家做IP难在哪？周鸿祎：要有勇气、胆量和厚脸皮

企业家做IP难在哪？周鸿祎：要有勇气、胆量和厚脸皮

北京讯 6月6日，在360AI新品发布会暨开发者沟通会上，360公司创始人、董事长兼CEO周鸿祎谈及了企业家做IP的看法。他表示，现在做IP比以前难了，企业家需要做好思想准备，要有勇气、胆量和厚脸皮，还要经得起放大镜的审视。

周鸿祎最初认为企业家做IP很容易，但现在他觉得很难。原因在于，现在的信息环境更加复杂，每个人都被置于放大镜下，一言一行都可能被误解或曲解。企业家如果做了错事或说了错话，就会被无限放大，甚至会身败名裂。

因此，周鸿祎认为，企业家做IP首先要做好思想准备，要成为一个高尚的人，脱离低级趣味，在道德上没有任何瑕疵。只有这样，才能经得起公众的审视。

此外，企业家做IP还需要有勇气、胆量和厚脸皮。因为在做IP的过程中，难免会遇到各种各样的困难和挫折，甚至会遭到一些人的攻击和谩骂。如果心理素质不强，很容易就会退缩。

周鸿祎还谈到，企业家做IP要坚持真我，不能为了博眼球而哗众取宠。只有真诚地与用户交流，才能赢得用户的尊重和信任。

近年来，越来越多的企业家开始尝试做IP，希望借此提升个人影响力和品牌知名度。然而，并非所有企业家都能成功做IP。周鸿祎的观点为企业家们做IP提供了一些有益的参考。

以下是对新闻稿的几点补充：

• 文章开头使用了一个新标题，更加简洁明了，也更加吸引人。
• 文章对周鸿祎的观点进行了概括和总结，使内容更加清晰。
• 文章补充了一些背景信息，使读者更容易理解新闻内容。
• 文章的语言更加流畅，用词更加严谨。

希望这篇新闻稿能够符合您的要求。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.